Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00392678 · ClinicalTrials.gov registry record · Phase 2

Targeting INflammation Using SALsalate in Type 2 Diabetes (TINSAL-T2D)

A Phase 2 study of Type 2 Diabetes, sponsored by Joslin Diabetes Center.

Completed
Registry status
Phase 2
Development phase
277
Enrollment target
16
Study locations

NCT00392678 is a Phase 2 study of Type 2 Diabetes that has completed, run by Joslin Diabetes Center. The registered enrollment target is 277 participants, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (75% lower). The trial reports 16 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00392678, a Phase 2 study of Type 2 Diabetes, has completed, sponsored by Joslin Diabetes Center.

COMPLETED
Registry status
Phase 2
Development phase
277 participants
Enrollment target
16
Study locations

Study Summary

Growing evidence over recent years supports a potential role for low grade chronic inflammation in the pathogenesis of insulin resistance and type 2 diabetes. In this study we will determine whether salsalate, a member of the commonly used Non-Steroidal Anti-Inflammatory Drug (NSAID) class, is effective in lowering sugars in patients with type 2 diabetes. The study will determine whether salicylates represent a new pharmacological option for diabetes management. The study is conducted in two stages. The first stage is a dose ranging study, administering salsalate compared to placebo over three months. The primary objective of Stage 2 of the study is to evaluate the effects of salsalate on blood sugar control in diabetes; the tolerability of salsalate use in patients with type 2 diabetes (T2D); and the effects of salsalate on measures of inflammation, the metabolic syndrome, and cardiac risk. The second stage is a second trial and posted under alternate registration.

Conditions Studied

Type 2 Diabetes

Interventions

  • DRUG Placebo
  • DRUG Salsalate

Study Locations (16)

New York

  • Kaleida Health Center - Buffalo
  • North Shore Diabetes and Endocrine Associates - New Hyde Park
  • Columbia University - New York
  • University of Rochester Medical Center - Rochester

Georgia

  • Kaiser Permanente - Atlanta
  • Emory School of Medicine - Atlanta

Connecticut

  • Chapel Medical Group - New Haven

District of Columbia

  • MedStar Research Institute - Washington D.C.

Florida

  • Endocrine Clinical Research - Winter Park

Illinois

  • University of Illinois at Chicago - Chicago

Louisiana

  • Tulane University - New Orleans

Massachusetts

  • Joslin Diabetes Center - Boston

Trial Details

FieldValue
Enrollment Target 277 participants
Start Date 2006-10
Est. Completion 2010-12
Phase Phase 2

Sponsor

Joslin Diabetes Center

73 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00392678

The ClinicalTrials.gov registry entry for NCT00392678 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 277 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (75% lower). The listed sponsor is Joslin Diabetes Center, which has 73 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00392678 reports 16 study locations spanning 12 distinct geographic areas - top geographies include New York, Georgia, Connecticut.

Frequently Asked Questions

What is clinical trial NCT00392678 about?

NCT00392678 is a clinical study titled "Targeting INflammation Using SALsalate in Type 2 Diabetes (TINSAL-T2D)". Growing evidence over recent years supports a potential role for low grade chronic inflammation in the pathogenesis of insulin resistance and type 2 diabetes. In this study we will determine whether salsalate, a member of the commonly used Non-Steroidal Anti-Inflammatory Drug (NSAID) class, is effec...

What is the current status of trial NCT00392678?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 277 participants. The study started on 2006-10. Estimated completion is 2010-12.

What conditions does trial NCT00392678 study?

This clinical trial studies the following conditions: Type 2 Diabetes.

What interventions are being tested in trial NCT00392678?

The interventions under investigation include: Placebo (DRUG), Salsalate (DRUG).

Who is sponsoring clinical trial NCT00392678?

This trial is sponsored by Joslin Diabetes Center, which has 73 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00392678 being conducted?

This trial has 16 study locations across Connecticut, District of Columbia, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Type 2 Diabetes

All registered trials for this condition

Connecticut

All trials with a study site in Connecticut

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.